



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/621,092	07/21/2000	Solomon S. Steiner	PDC 116 4836		
23579	7590 10/21/2003		EXAMINER		
PATREA L.		PATEL, MITAL B			
HOLLAND & KNIGHT LLP SUITE 2000, ONE ATLANTIC CENTER			ART UNIT	PAPER NUMBER	
1201 WEST PEACHTREE STREET, N.E. ATLANTA, GA 30309-3400		Е.	3743 DATE MAILED: 10/21/2003	15	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary		Application No.		Applicant(s)				
		09/621,092		STEINER ET AL.				
		Examiner		Art Unit				
		Mital B. Patel		3743	Idea a a			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status								
1)⊠	Responsive to communication(s) filed on 08 S	September 2003 .		•				
2a)□	This action is FINAL . 2b)⊠ Thi	is action is non-fir	nal.					
3)[
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims								
•	Claim(s) 28-30,41 and 43-45 is/are pending in	the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.								
5)								
6)⊠ Claim(s) <u>30,41 and 43-45</u> is/are rejected.								
7)⊠	7)⊠ Claim(s) <u>28,29</u> is/are objected to.							
8) Claim(s) are subject to restriction and/or election requirement. Application Papers								
· · · _	The specification is objected to by the Examine	r.			,			
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a)	☐ All b)☐ Some * c)☐ None of:							
	1. Certified copies of the priority documents	s have been recei	ved.					
	2. Certified copies of the priority documents have been received in Application No							
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachment(s)								
2) Notice 3) Infor	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5)		(PTO-413) Paper No atent Application (PT				
I.S. Patent and 1 PTOL-326 (F	Trademark Office Rev. 04-01) Office Ac	tion Summary		Part of	Paper No. 17			

Application/Control Number: 09/621,092 Page 2

Art Unit: 3743

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/8/03 has been entered.

Response to Amendment/Arguments

- 2. Applicant's arguments filed 9/8/03 have been fully considered but they are not persuasive.
- 3. In response to applicant's arguments that Yang does not suggest the use of this capsule in an inhaler, a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. In a claim drawn to a process of making, the intended use must result in a manipulative difference as compared to the prior art. See *In re Casey*, 152 USPQ-235 (CCPA 1967) and *In re Otto*, 136 USPQ 458, 459 (CCPA 1963).
- 4. In response to Applicant's arguments with respect to the keying surface located on outer surface of the closed end of a capsule, please note that the Examiner also

Application/Control Number: 09/621,092

Art Unit: 3743

designated 3' to be a keying surface and as depicted in Figure 4, both 3' and 7 are on the outer surface of the closed end of the capsule.

- 5. In response to Applicant's arguments that Yang does not disclose a keying surface orienting the capsule within the inhaler, it should be noted that the inhaler is not positively recited.
- 6. In response to Applicant's arguments that Yang does not disclose a capsule wherein the keying surface identifies the drug to be placed in the capsule, it should be noted that Applicant has not provided any other structure than the keying surface which the Examiner maintains is taught by Yang to identify the drug that is placed in the capsule.

Claim Rejections - 35 USC § 102

7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 8. Claims 30, 41, 43-45 are rejected under 35 U.S.C. 102(b) as being anticipated by Yang (US 5632971).
- 9. **As to claim 41**, Yang teaches a capsule to contain drug for use in an inhaler comprising a keying surface on an outside surface of a closed end of the capsule (The Examiner considers the slots **3',7** to be keying surfaces) that is adapted to orient the capsule within the inhaler or identifies the drug to be placed in the capsule.

Application/Control Number: 09/621,092

Art Unit: 3743

- 10. **As to claim 30**, Yang teaches a capsule further including medicament selected from the group consisting of liquid, powder, and gaseous medicaments.
- 11. **As to claim 43**, Yang teaches a capsule wherein the keying surface is adapted to orient the capsule within the inhaler.
- 12. **As to claim 44**, Yang teaches a capsule further comprising a keying surface identifying the drug to be placed in the capsule.
- 13. **As to claim 45**, Yang teaches a capsule comprising a keying surface on the outside of one end which is adapted to orient the capsule within the inhaler and a keying surface on the other end which identifies the drug to be placed in the capsule.

Allowable Subject Matter

14. Claims 28 and 29 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mital B. Patel whose telephone number is 703-306-5444. The examiner can normally be reached on Monday-Friday (8:00 - 4:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Henry Bennett can be reached on 703-308-0101. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Application/Control Number: 09/621,092

Art Unit: 3743

Page 5

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0858.

mbp

Aaron J. Lewis Primary Examiner